Finance

Senarai
BIOCON:NSE
Biocon Ltd
₹346.35
-0.87%
(-3.05) 1H
12 Okt, 3:30:00 PTG GMT+5:30  ·   INR
Semua simbol
SimbolHargaPerubahan% Perubahan
Menjana cerapan popular untuk BIOCON...
Buka
₹348.10
Tinggi
₹351.80
Rendah
₹345.10
Permodalan Pasaran
564.14B
Purata volum
3.08J
Volum
2.63J
Dividen
0.14%
Dividen suku tahunan
₹0.13
Tarikh tanpa dividen
3 Jul 2026
Nisbah H/P
102.54
tgi 52 mgu
₹447.15
rdh 52 mgu
₹337.70
EPS
₹3.38
Syer tertunggak
600.00J
Bilangan pekerja
16K
Buka
₹348.10
Tinggi
₹351.80
Rendah
₹345.10
Permodalan Pasaran
564.14B
Purata volum
3.08J
Volum
2.63J
Dividen
0.14%
Dividen suku tahunan
₹0.13
Tarikh tanpa dividen
3 Jul 2026
Nisbah H/P
102.54
tgi 52 mgu
₹447.15
rdh 52 mgu
₹337.70
EPS
₹3.38
Syer tertunggak
600.00J
Bilangan pekerja
16K
Cerita berita
Daripada sumber web dan rakan kongsi berita
Profil
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Perihal Biocon Ltd
CEOShreehas P Tambe
Pekerja16.4K
Diasaskan29 Nov 1978
Ibu pejabatBangalore, Karnataka, India
Sektor-
Laman webbiocon.com
Laporan terakhir
6 Ogo 2026
Tempoh fiskal
S1 2027
₹0.95 / ₹1.09
-12.68%tersasar
Hasil / Anggaran (INR)
43.36B / 44.74B
-3.08%tersasar
Panggilan persidangan pendapatan fiskal Suku Pertama 2027
Menunggu panggilan persidangan pendapatan
Sekilas pandang
Cerapan daripada berita dan laporan terkini
Laporan sebelumnyaSemua nilai dalam INR
Loading Previous Earnings...
Hasil
Pendapatan bersih
Semua nilai dalam INR
Sep 2025
Dis 2025
Mac 2026
Jun 2026
Hasil
42.96B
41.73B
45.17B
43.36B
Kos barangan yang dijual
17.72B
13.39B
23.69B
14.68B
Kos hasil
17.72B
13.39B
23.69B
14.68B
Perbelanjaan penyelidikan dan pembangunan
-132.00J
-531.00J
-128.00J
-16.00J
Jumlah perbelanjaan penyelidikan dan pembangunan
-
-
-
-
Perbelanjaan jualan, am dan pentadbiran
9.59B
8.75B
13.28B
9.16B
Belanja kendalian
21.18B
25.16B
14.45B
25.69B
Jumlah belanja kendalian
38.90B
38.55B
38.14B
40.36B
Pendapatan kendalian
4.05B
3.18B
7.03B
3.00B
Pendapatan bukan kendalian lain
94.00J
1.17B
-2.52B
545.00J
EBT termasuk item luar biasa
1.71B
-678.00J
2.48B
1.28B
EBT tidak termasuk item luar biasa
1.23B
2.26B
1.80B
1.41B
Belanja cukai pendapatan
385.00J
-160.00J
489.00J
-92.00J
Kadar cukai berkesan
22.48%
23.60%
19.76%
-7.21%
Belanja kendalian lain
6.72B
11.78B
-4.12B
11.07B
Pendapatan bersih
845.00J
1.44B
1.26B
1.41B
Margin untung bersih
1.97%
3.45%
2.79%
3.25%
Perolehan bagi setiap syer
0.72
2.74
1.27
0.95
Pendapatan faedah dan pelaburan
235.00J
-
1.15B
-
Belanja faedah
-2.72B
-2.10B
-2.06B
-2.13B
Belanja faedah bersih
-2.49B
-2.10B
-906.00J
-2.13B
Caj susut nilai dan pelunasan
4.73B
5.15B
5.13B
5.47B
EBITDA
8.69B
7.13B
11.62B
7.59B
Keuntungan atau kerugian daripada jualan aset
-
-
-
-
Kandungan AI boleh mengandungi kesilapan. Ketahui lebih lanjut
BantuanHantar maklum balasPrivasiSyaratPenafian
Apl Google